CD4 and neoplasm: This is an important question, as circulating, blood cytotoxic CD4+ T cells that communicate with the tumor would share antigenic specificity with their tumor-resident counterparts, making them an accessible means to monitor intratumoral immunity or to develop ex vivo cellular therapies.